JMP analyst reiterates Market Outperform rating on Inovio stock

JMP Securities reiterated its Market Outperform rating and $12.00 price target for Inovio Pharmaceuticals (INO), signaling significant upside from its current $1.49 price despite a weak InvestingPro financial health score. The company is advancing its INO-3107 program, on track for a Biologics License Application (BLA) by late 2025, with JMP expecting high approval likelihood following a requested rolling FDA submission. Financially, Inovio reported a significant reduction in Q2 2025 losses, cutting operating expenses by 31% and nearly halving net loss per share, demonstrating effective cost management and a potentially stabilizing financial trajectory, supported by $47.5 million in cash and recent $22.5 million net cash addition.

Analysis

JMP Securities has reaffirmed its Market Outperform rating on Inovio Pharmaceuticals (INO) with a $12.00 price target, suggesting substantial upside from the current price of $1.49. This positive outlook is primarily driven by the progress of its drug candidate, INO-3107, which is on track for a Biologics License Application (BLA) submission by the end of 2025. JMP considers approval "highly likely" and notes the company has requested a rolling submission from the FDA, with acceptance anticipated this month. Financially, Inovio has demonstrated disciplined cost management, reducing Q2 operating expenses by 31% and cutting its net loss per share by nearly half. The company's liquidity appears stable in the medium term, with $47.5 million in cash at quarter-end, an additional $22.5 million raised in July, and a projected cash runway into the second quarter of 2026. However, this optimism is tempered by a weak InvestingPro financial health score of 1.71 out of 5 and an imminent competitive threat from Precigen (PGEN), which has a PDUFA date of August 27 for a rival product.

Key Decisions for Investors

• Investors with a high risk tolerance may consider the significant disparity between the current stock price and JMP's $12.00 target as a speculative opportunity contingent on the successful regulatory progression of INO-3107.
• It is crucial to monitor the near-term competitive risk posed by Precigen's PDUFA date on August 27, as a competitor approval could impact INO-3107's market potential.
• Carefully weigh the analyst's bullish stance against the company's weak underlying financial health score of 1.71/5 and track cash burn rates to ensure the runway remains sufficient to reach the planned BLA submission in late 2025.